

Claudio Vernieri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7936495/claudio-vernieri-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	1,266 citations	18 h-index	34 g-index
67 ext. papers	1,810 ext. citations	8.6 avg, IF	4.41 L-index

#	Paper	IF	Citations
64	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079123	5.4	1
63	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. <i>Nature Cancer</i> , 2022 , 3, 251-261	15.4	3
62	Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. <i>Cell Metabolism</i> , 2021 , 33, 2247-2259.e6	24.6	6
61	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211006960	5.4	1
60	Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. <i>Cancer Discovery</i> , 2021 ,	24.4	15
59	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455 ²	12.9	5
58	The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. <i>Cancers</i> , 2021 , 13,	6.6	13
57	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021 , 511, 77-87	9.9	7
56	Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. <i>Oncology</i> , 2021 , 99, 84-95	3.6	2
55	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
54	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021 , 13,	6.6	6
53	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. <i>Cancers</i> , 2021 , 13,	6.6	3
52	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. <i>Developmental Cell</i> , 2021 , 56, 2607-2622.e6	10.2	1
51	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020 , 11, 2332	17.4	42
50	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020 , 12,	6.6	1
49	Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
48	Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. <i>Cells</i> , 2020 , 9,	7.9	13

47	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020 , 26, 992-994	50.5	19
46	Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. <i>Pharmacology & Therapeutics</i> , 2020 , 209, 107496	13.9	31
45	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , 2020 , 9,	7.9	4
44	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020 , 583, 620-624	40.4	79
43	Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
42	Beyond Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	3
41	mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020 , 5, e000748	6	1
40	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. <i>Nature Communications</i> , 2020 , 11, 4274	17.4	10
39	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820927271	4.7	3
38	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. <i>Cells</i> , 2020 , 9,	7.9	5
37	Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920970081	5.4	2
36	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , 2020 , 271, 527-533	7.8	27
35	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020 , 22, 33	8.3	14
34	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019 , 9, 12993	4.9	11
33	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 53-66	7	68
32	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019 , 4, e000457	6	93
31	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019 , 11,	6.6	10
30	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019 , 234, 1768-1779	7	25

29	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019 , 42, 815-828	7.2	9
28	The of a New Way to Value Myeloid Immunosuppression in Cancer. <i>Cancer Research</i> , 2019 , 79, 3169-3171	10.1	1
27	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 902	5.3	5
26	Cellular response upon proliferation in the presence of an active mitotic checkpoint. <i>Life Science Alliance</i> , 2019 , 2,	5.8	1
25	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019 , 24, 385-393	5.7	15
24	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019 , 19, e306-e318	3	9
23	Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019 , 20, e413-e417	4.9	15
22	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019 , 144, 1704-1712	7.5	9
21	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 123, 57-73	7	26
20	Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. <i>Current Biology</i> , 2018 , 28, 28-37.e7	6.3	7
19	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
18	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 607-618	5.7	13
17	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
16	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. <i>Scientific Reports</i> , 2018 , 8, 8703	4.9	31
15	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1692-1704	8.9	49
14	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 365-373	4.4	10
13	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017 , 13, 1677-1683	3.6	4
12	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 183-188	5.4	17

11	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 347-352	8.7	22
10	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2414-2422	12.9	111
9	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 969-76	3.5	4
8	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016 , 6, 1315-1333	14.4	107
7	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016 , 7, 44841-44847	3.3	9
6	Urachal carcinoma: towards a precision medicine. <i>Translational Cancer Research</i> , 2016 , 5, S1307-S1310	0.3	3
5	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016 , 9, 432-439	1	2
4	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016 , 12, 1251-60	3.6	19
3	The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. <i>Journal of Cell Science</i> , 2014 , 127, 4381-95	5.3	15
2	Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2A ^{Cdc55} . <i>Journal of Cell Biology</i> , 2013 , 202, 765-78	7.3	15
1	Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction. <i>EMBO Journal</i> , 2011 , 30, 1508-19	13	149